Isofol Medical AB (publ) (STO:ISOFOL)
Sweden · Delayed Price · Currency is SEK 0.8780
-0.0150 (-1.68%)
Aug 13, 2026, 5:29 PM CET
Isofol Medical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | 0.72 | 12.8 | 22.41 | |
Revenue Growth | - | - | - | -94.37% | -42.89% | -39.66% |
Gross Profit | - | - | - | 0.72 | 12.8 | 22.41 |
Selling, General & Admin | 5.59 | 54.76 | 47.21 | 42.56 | 178.46 | 224.43 |
Depreciation & Amortization Expenses | - | - | 0 | 0.04 | 0.07 | 1.6 |
Research & Development | 10.17 | - | - | - | - | - |
Other Operating Expenses | -0.11 | 1.22 | -0.01 | -0.19 | 1.81 | 0.84 |
Total Operating Expenses | 15.65 | 55.98 | 47.21 | 42.41 | 180.34 | 226.87 |
Operating Income | -57.52 | -55.98 | -47.21 | -41.68 | -167.54 | -204.47 |
Interest Income | 1.94 | 1.82 | 3.72 | 4.62 | 7.75 | 4.38 |
Interest Expense | - | -0 | - | -0.01 | - | -0.17 |
Total Non-Operating Income (Expense) | 1.94 | 1.82 | 3.72 | 4.61 | 7.75 | 4.22 |
Pretax Income | -55.57 | -54.17 | -43.49 | -37.07 | -159.79 | -200.25 |
Net Income | -55.57 | -54.17 | -43.49 | -37.07 | -159.79 | -200.25 |
Net Income to Common | -55.57 | -54.17 | -43.49 | -37.07 | -159.79 | -200.25 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 232 | 217 | 162 | 162 | 162 | 126 |
Shares Outstanding (Diluted) | 232 | 217 | 162 | 162 | 162 | 126 |
Shares Change | 430.20% | 34.49% | - | - | 28.55% | 104.40% |
EPS (Basic) | -0.24 | -0.25 | -0.27 | -0.23 | -0.99 | -1.59 |
EPS (Diluted) | -0.24 | -0.25 | -0.27 | -0.23 | -0.99 | -1.59 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -55.58 | -51.94 | -41.99 | -52.54 | -192.68 | -188.43 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.24 | -0.24 | -0.26 | -0.33 | -1.19 | -1.50 |
Gross Margin | - | - | - | 100.00% | 100.00% | 100.00% |
Operating Margin | - | - | - | -5781.28% | -1309.24% | -912.50% |
Profit Margin | - | - | - | -5141.61% | -1248.68% | -893.70% |
FCF Margin | - | - | - | -7286.55% | -1505.67% | -840.94% |
EBITDA | -57.52 | -55.98 | -47.21 | -41.65 | -167.54 | -204.47 |
EBITDA Margin | - | - | - | -5776.14% | -1309.24% | -912.50% |
EBIT | -57.52 | -55.98 | -47.21 | -41.68 | -167.54 | -204.47 |
EBIT Margin | - | - | - | -5781.28% | -1309.24% | -912.50% |